Caki-2: Human Renal Cancer Cell Line (ATCC HTB-47)

SK2010-068

Description

Caki-2 is a human clear cell renal cell carcinoma (ccRCC) line that displays epithelial morphology and grows in adherent culture. These cells are a useful preclinical model to study renal cancer. They are relatively less sensitive to 5-fluorouracil and sorafenib (multi-kinase inhibitor of VEGFRs 1-3, PDGFR-b, and Raf-1) compared to Caki-1 cells. The Caki-2 cells have a loss-of-function mutation in the von Hippel-Lindau (VHL) tumor-suppressor protein and are known to form tumors in immunocompromised mice.

Source

This cell line was established in 1971 from the primary tumor of a 69-year-old Caucasian male with clear cell carcinoma of the kidney.

Inventors

  • Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
  • Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Miyake M et al. (2012) 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncology Letters 3: 1195–1202 (PubMed ID: 22783417)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.

To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at bugaa@mskcc.org.  Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.

For licensing requests for a commercial purpose:  Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications